Telix Pharmaceuticals Ltd
TLXHealthcare|Biotechnology|Australia
$11.14
-0.65 (-5.47%)
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
967.49,
1142.47,
1274.18,
1879.84,
1477.76
],
"ebit_estimate": [
48.65,
99.28,
157.33,
424.27,
262.08
],
"ebitda_estimate": [
70.08,
127.94,
160.21,
570.05,
268.2
],
"net_income_estimate": [
14.04,
45.78,
104.06,
345.43,
205.56
],
"per_share_eps_estimate": [
0.05,
0.15,
0.34,
0.59,
0.74
],
"eps_nri_estimate": [
0.04,
0.13,
0.31,
1.24,
0.62
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
1.21,
1.56,
1.55,
4.02,
4.42
],
"pretax_income_estimate": [
22.14,
87.38,
184.9,
232.7,
350.9
],
"operating_cash_flow_per_share_estimate": [
0.23,
0.39,
0.6,
2.18,
1.02
],
"roa_estimate": [
1.27,
5.47,
9.58,
21.76,
9.09
],
"roe_estimate": [
4.14,
11.42,
14.77,
36.84,
16.15
],
"gross_margin_estimate": [
55.8,
57.42,
57.6,
60.5,
62
],
"operating_cash_flow_estimate": [
72,
120.42,
185.44,
677.83,
317.5
],
"pettm_estimate": [
218.43,
76.83,
32.86,
19.04,
15.16
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "17.91",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 17.91,
"future_ebit_estimate_growth": 67.45,
"future_ebitda_estimate_growth": 55.48,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 8.6,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 2.07,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202612",
"202706"
],
"revenue_estimate": [
459.13,
505.69,
541.5
],
"ebit_estimate": [
21.09,
39.3,
51
],
"ebitda_estimate": [
49,
14,
null
],
"net_income_estimate": [
12.25,
15.58,
11.59
],
"per_share_eps_estimate": [
0.04,
0.08,
0.09
],
"eps_nri_estimate": [
0.03,
0.06,
0.04
],
"dividend_estimate": [
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null
],
"pretax_income_estimate": [
15.25,
32.25,
38
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null
],
"roa_estimate": [
null,
null,
null
],
"roe_estimate": [
null,
null,
null
],
"gross_margin_estimate": [
56,
56,
null
],
"operating_cash_flow_estimate": [
null,
null,
null
],
"pettm_estimate": [
95.21,
65.15,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "17.91",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 17.91,
"future_ebit_estimate_growth": 67.45,
"future_ebitda_estimate_growth": 55.48,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 8.6,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 2.07,
"future_operating_cash_flow_per_share_estimate_growth": null
}